NCT02412462View on ClinicalTrials.gov

Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Solid TumorMetastatic Cancer
Interventions
DRUG

AB-16B5

Trial Locations (1)

H3T 1E2

Jewish General Hospital, Montreal

Sponsors
All Listed Sponsors
lead

Alethia Biotherapeutics

INDUSTRY

NCT02412462 - Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy | Biotech Hunter | Biotech Hunter